drugset / Trial / NCT06807593
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
Phase 2
Recruiting
10 enrolled
M.D. Anderson Cancer Center
Janssen Research & Development, LLC · collab
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to learn if ustekinumab can help to control immune-related diarrhea and/or colitis in cancer patients.
Timeline
- Start
- 2026-02-24
- Primary completion
- 2027-03-31
- Completion
- 2027-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ustekinumab | Monoclonal antibody | — | Other |